Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 464-468

  Payne, Brendan A I ^a   Nsutebu, Emmanuel F ^b   Hunter, Ewan R ^c   Olarinde, Olufunso ^d   Collini, Paul ^d   Dunbar, James A T ^e   Basta, Medhat S T ^c   Elston, James W T ^f   Schmid, Matthias L ^c   Thaker, Hiten ^f   Chadwick, David R ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV drug resistance resistance mutations; Knowledge attitude practice studies

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEGRO; NONHUMAN; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDY; UNITED KINGDOM; VIRUS MUTATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 49649106539     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn228     Document Type: Article

References (10)

1. Gazzard B, Bernard EJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6: 1-61.
2. Booth CL, Garcia-Diaz AM, Youle M et al. Prevalence and predictors of transmitted antiretroviral resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59: 517-24.
3. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 2005; 331: 1368-73.
4. Johnson VA, Brun-Vézinet F, Bonaventura C et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14: 125-30.
5. The UK Collaborative Group for HIV and STI Surveillance. A Complex Picture. HIV and Other Sexually Transmitted Infections in the United Kingdom: 2006. London: Health Protection Agency, Centre for Infections, November 2006.
6. Gandhi RT, Wurcel A, Rosenberg ES et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a mutiply drug-resistant virus. Clin Infect Dis 2003; 37: 1693-8.
7. Pao D, Andrady U, Clarke J et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J AIDS 2004; 37: 1570-3.
8. Wensing AMJ, van der Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 958-66.
9. Kozal MJ, Amico KR, Chiarella J et al. Antiretroviral resistance and high-risk transmission behaviour among HIV-positive patients in clinical care. AIDS 2004; 18: 2185-9.
10. UK Collaborative Group on HIV Drug Resistance. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21: 1035-9.